| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023457737 |
| P356 | DOI | 10.1038/SREP27232 |
| P8608 | Fatcat ID | release_spe3le4m2jcgtfjtqp373tcupy |
| P3181 | OpenCitations bibliographic resource ID | 1015114 |
| P932 | PMC publication ID | 4893706 |
| P698 | PubMed publication ID | 27265565 |
| P50 | author | Estela Noguera-Ortega | Q57145677 |
| Eduard Torrents | Q73377839 | ||
| Núria Blanco-Cabra | Q88987486 | ||
| Esther Julián | Q42707034 | ||
| Alejandro Sánchez-Chardi | Q43237278 | ||
| P2093 | author name string | Marina Luquin | |
| Rosa Maria Rabanal | |||
| Mónica Roldán | |||
| Sandra Guallar-Garrido | |||
| P2860 | cites work | The glycan-rich outer layer of the cell wall of Mycobacterium tuberculosis acts as an antiphagocytic capsule limiting the association of the bacterium with macrophages | Q24561597 |
| Effect of cetylpyridinium chloride on microbial adhesion to hexadecane and polystyrene | Q24672014 | ||
| Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy | Q26774965 | ||
| The production of a new extracellular putative long-chain saturated polyester by smooth variants of Mycobacterium vaccae interferes with Th1-cytokine production | Q28237723 | ||
| Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer | Q34048705 | ||
| An integrated surrogate model for screening of drugs against Mycobacterium tuberculosis | Q34187856 | ||
| Antitumor activity of mycobacterial glycolipid A1 | Q34455587 | ||
| Best practice in the treatment of nonmuscle invasive bladder cancer | Q35688392 | ||
| Fibronectin attachment protein from bacillus Calmette-Guerin as targeting agent for bladder tumor cells | Q35748491 | ||
| Role of urothelial cells in BCG immunotherapy for superficial bladder cancer | Q35842140 | ||
| Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. | Q52544224 | ||
| Cytokine Gene Expression in a Mouse Model: The First Instillations With Viable bacillus Calmette-Guerin Determine the Succeeding Th1 Response | Q54750303 | ||
| Connaught and Russian Strains Showed the Highest Direct Antitumor Effects of Different Bacillus Calmette-Guérin Substrains | Q60639123 | ||
| Biologically active components from mycobacterial cell walls. II. Suppression and regression of strain-2 guinea pig hepatoma | Q68676400 | ||
| Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results | Q69897065 | ||
| Time-dependent aggregation of reconstituted BCG vaccine | Q72820721 | ||
| Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin | Q73050478 | ||
| Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity | Q73574127 | ||
| What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? | Q73676467 | ||
| Optimizing syngeneic orthotopic murine bladder cancer (MB49) | Q77926069 | ||
| The fibronectin attachment protein of bacillus Calmette-Guerin (BCG) mediates antitumor activity | Q81041189 | ||
| BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model | Q81864824 | ||
| Intravesical therapy for bladder cancer | Q86933526 | ||
| ANALYZING TABLES OF STATISTICAL TESTS | Q88207206 | ||
| The perfect mix: recent progress in adjuvant research | Q36844715 | ||
| Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy | Q37540810 | ||
| Catheter-related bloodstream infection caused by Mycobacterium brumae | Q37597416 | ||
| The Behaviour of Acid-fast Bacteria in Oil and Water Systems | Q37675786 | ||
| Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer. | Q37773294 | ||
| Intravesical drug delivery: Challenges, current status, opportunities and novel strategies | Q37787341 | ||
| Bacillus Calmette-Guérin immunotherapy for genitourinary cancer | Q38091720 | ||
| The mechanism of action of BCG therapy for bladder cancer--a current perspective | Q38184849 | ||
| Nonpathogenic Mycobacterium brumae Inhibits Bladder Cancer Growth In Vitro, Ex Vivo, and In Vivo. | Q38672153 | ||
| Nanoparticulation of BCG-CWS for application to bladder cancer therapy | Q39037472 | ||
| Permeation enhancer-containing water-in-oil nanoemulsions as carriers for intravesical cisplatin delivery | Q39817116 | ||
| Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. | Q39984765 | ||
| Mechanisms of phagocytosis of Mycobacterium leprae and other mycobacteria by human oligodendroglial cells | Q40166090 | ||
| Draft Genome Sequence of Mycobacterium brumae ATCC 51384. | Q40695016 | ||
| BCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell lines. | Q41021678 | ||
| γ Irradiated Mycobacteria Enhance Survival in Bladder Tumor Bearing Mice Although Less Efficaciously than Live Mycobacteria. | Q41112688 | ||
| The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines | Q41118113 | ||
| A Staphylococcus aureus ypfP mutant with strongly reduced lipoteichoic acid (LTA) content: LTA governs bacterial surface properties and autolysin activity | Q42109382 | ||
| Misdiagnosis of Mycobacterium brumae infection | Q42706987 | ||
| The impact of the absence of glycopeptidolipids on the ultrastructure, cell surface and cell wall properties, and phagocytosis of Mycobacterium smegmatis | Q44170676 | ||
| Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy | Q44782208 | ||
| Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin | Q45004129 | ||
| Mycobacterium brumae sp. nov., a Rapidly Growing, Nonphotochromogenic Mycobacterium | Q45312158 | ||
| Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. | Q47655009 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | olive oil | Q93165 |
| P304 | page(s) | 27232 | |
| P577 | publication date | 2016-06-06 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment | |
| P478 | volume | 6 |
Search more.